AstraZeneca

EU clears AstraZeneca’s new 'Brilique’ dosage for extended treatment of heart patients

19 Feb 2016

UK drugmaker AstraZeneca agrees to acquire majority stake in Acerta Pharma

18 Dec 2015

AstraZeneca boost oncology portfolio with $4bn Acerta Pharma deal

17 Dec 2015

AstraZeneca to acquire Takeda’s respiratory business for $575 million

16 Dec 2015

AstraZeneca to sell the US rights of Crohn disease drug Entocort to Perrigo

24 Nov 2015

AstraZeneca to buy ZS Pharma for $2.7 bn

06 Nov 2015

US FDA approves AstraZeneca’s new dosage for heart drug 'Brilinta'

04 Sep 2015

Valeant to buy rights to AstraZeneca's psoriasis drug

01 Sep 2015

Sanofi to buy AstraZeneca's cancer drug for upto $300 mn

27 Jul 2015

AstraZeneca to sell gastrointestinal drug Entocort to Tillotts Pharma

09 Jul 2015

AstraZeneca,Juno partner to study immune therapy drugs

24 Apr 2015

New pill by AstraZeneca shown to delay lung cancer progression by more than a year

20 Apr 2015

New AIIMS, hike in health policy premiums welcome

28 Feb 2015

AstraZeneca acquires Actavis’s respiratory business for $600 million

06 Feb 2015

AstraZeneca strikes three oncology deals

04 Nov 2014

British pharmaceutical company AstraZeneca today struck three deals to strengthen its oncology business

Pfizer's $11-bn share repurchase ends chances of renewed bid for AstraZeneca

25 Oct 2014

US drugmaker Pfizer’s board yesterday authorised a new $11-billion share repurchase plan, which analysts say puts an end to speculations that it would renew its bid for British rival AstraZeneca

US government clears AstraZeneca’s Brilinta over concerns related to trial process

20 Aug 2014

AstraZeneca to acquire rights to Almirall’s lung drugs

30 Jul 2014

AstraZeneca, Roche, Qiagen in collaboration on lung cancer tests

28 Jul 2014

AstraZeneca plans £330m R&D centre and corporate HQ in Cambridge

18 Jul 2014

AstraZeneca India delisting under Sebi lens for cheating investors

25 Jun 2014

Sebi says it would take appropriate measures in order to protect the interest of retail investors in the delisting process

US FDA gives `fast-track’ status for AstraZeneca’s novel antibiotic for treatment of gonorrhea

04 Jun 2014

Pfizer drops AstarZeneca take over bid

28 May 2014

AstraZeneca rejects Pfizer’s third takeover offer

19 May 2014

AstraZeneca said that Pfizer’s tax-driven inversion structure, which is a key part of its proposal, has already been the subject of intense public and governmental scrutiny

Pfizer raises bid for AstraZeneca to $118.8 bn, says latest offer is final

19 May 2014